PCSK9 inhibitors (Liphorus)

N/A

Report date: 2025/01/26 19:22:18
NME

Base Information

Drug NamePCSK9 inhibitors (Liphorus)
Drug Alias NamePCSK9 inhibitors (University of Montreal)PCSK9 inhibitors (University of Montreal)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemiaCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversite De Montreal
China Registration ClassN/A

Develop Information

Active CompaniesLiphorus Pharmaceuticals Inc
Inactive CompaniesUniversite De MontrealUnivalor
Active IndicationsHypercholesterolemiaCardiovascular Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A